|
|||||
|
|
Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis |
|
| Authors: | Koji Sasaki MD Elias J. Jabbour MD Farhad Ravandi MD Nicholas J. Short MD Deborah A. Thomas MD Guillermo Garcia‐Manero MD Naval G. Daver MD Tapan M. Kadia MD Marina Y. Konopleva MD PhD Nitin Jain MD Ghayas C. Issa MD Vicki Jeanis RN Haim G. Moore Rebecca S. Garris BA Naveen Pemmaraju MD Jorge E. Cortes MD Susan M. O'Brien MD Hagop M. Kantarjian MD |
| Affiliation: | 1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;3. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas;4. Clinical Science, Chao Family Comprehensive Cancer Center, University of California at Irvine, Orange, California |
| Abstract: | |
| Keywords: | acute lymphoblastic leukemia dasatinib hyperfractionated cyclophosphamide vincristine doxorubicin dexamethasone (hyper‐CVAD [HCVAD]) Philadelphia chromosome ponatinib |